Jul
18
2019
On demand
Optimizing the workflow for therapeutic viral vectors – upstream and downstream
Sponsor
As an industry we can make viral vectors. Now it is time to refine processes to achieve the yield and quality needed to support research, development, and commercialization while controlling costs. Collectively, small changes in unit operations can have a big impact on developing a process that is efficient and scalable, yet flexible enough to adapt over time.
Watch this on demand webinar with Dr Spencer Hoover, Director of Process and Analytical Development – Centre for Advanced Therapeutic Cell Technologies, Centre for Commercialization of Regenerative Medicine (CCRM), Dr Lesley Chan, Senior Scientist, Vector Process Development, Bluebird Bio and Francesca Bellintani, Downstream Process Development Manager, MolMed.
- Understand the key challenges with viral vector production and identify the major bottleneck steps
- Find out how industry leaders are currently addressing issues with current production volumes and titers, and seeking to alleviate the capacity crunch
- Get updated on the latest advances with stable producer cell lines and improved purification techniques
- Gain high-level regulatory insights around viral vector bioprocessing
You might also like
Focus on allogeneic CAR-Ts manufacturing challenges and solutions
M Langtry, A Sargent, B Baghbaderani
15 March 2023
Simplifying GMP CAR-T and CAR NK cell therapy manufacturing processes
M Luevano, X Wang, S Fricke et al.
9 June 2022
Large-scale LVV production: from industry-leading process development to high quality GMP vector
25 February 2021
Exploring the capabilities of a versatile, novel, automated closed system for cell and gene therapy manufacturing
16 February 2021
Fitting product to process: raw materials customization for cell therapy manufacturing success
J Tomtishen III, L Clarke, PhD, L Belcastro et al.
11 February 2021